Skip to main content
TMSList
Comparison

MagVenture vs BrainsWay: Deep TMS vs Figure-8 Coil Comparison

How does MagVenture's figure-8 coil compare to BrainsWay's H-coil deep TMS system? Coverage, efficacy, FDA clearances, and which clinics use each.

MagVenture
VS
BrainsWay

The Verdict: tie

BrainsWay has unique OCD clearance via deep TMS. MagVenture has broader international reach and a strong research pedigree. Both produce comparable depression outcomes.

MagVenture and BrainsWay represent two fundamentally different approaches to transcranial magnetic stimulation. One uses the established figure-8 coil design that pioneered modern TMS. The other introduced the H-coil to reach deeper brain structures — a difference that sounds small but affects everything from treatment depth to FDA indications.

What You’ll Learn

  • How MagVenture’s figure-8 coil and BrainsWay’s H-coil differ technically
  • Which FDA clearances each system holds
  • How outcomes compare for depression and OCD specifically
  • Where each system is available in the US
  • Insurance coverage differences between the two platforms

The Technical Difference: Coil Design

MagVenture uses the standard figure-8 coil design — two wing-shaped elements delivering magnetic pulses where the wings overlap. This creates a focused magnetic field that penetrates the prefrontal cortex effectively for standard depression treatment.

BrainsWay developed the H-coil, a proprietary design where the coil elements are arranged to direct the magnetic field deeper into the brain without increasing surface stimulation. The H-coil can stimulate the anterior cingulate and other subcortical structures that figure-8 coils reach less efficiently.

The practical implication: BrainsWay’s deep TMS covers a larger brain volume per pulse. This matters most for OCD, where the cingulate cortex — a deeper structure — is a key treatment target.

FDA Clearances

MagVenture holds FDA clearance for:

  • Major Depressive Disorder (treatment-resistant)
  • Obsessive-Compulsive Disorder (via MagVenture’s own protocol)
  • Smoking cessation

BrainsWay holds FDA clearance for:

  • Major Depressive Disorder (treatment-resistant)
  • Obsessive-Compulsive Disorder — the only TMS device with dedicated OCD clearance
  • Anxiety with comorbid depression

BrainsWay’s OCD clearance is significant. The indication came from large multicenter trials specifically targeting the condition. MagVenture’s OCD coverage typically relies on off-label protocols or clinical evidence from the BrainsWay trials.

Clinical Outcomes: Depression

For depression specifically, head-to-head data is limited. Both systems produce roughly equivalent response and remission rates in treatment-resistant populations — roughly 50-60% response and 30-35% remission for standard courses.

The key differentiator in depression treatment is logistics and clinic preference, not efficacy. If your psychiatrist recommends one system over the other, the choice usually reflects their clinical experience and which device their practice uses, not a meaningful outcome difference.

Clinical Outcomes: OCD

BrainsWay has a clear advantage for OCD patients. The OCD-specific clearance came from rigorous trials showing response rates around 40-50% in treatment-resistant OCD cases. The deeper H-coil targeting reaches the anterior cingulate more effectively.

MagVenture can treat OCD off-label, and some clinics use it successfully. But without the dedicated OCD indication, insurance coverage for OCD is more consistent with BrainsWay.

If you have comorbid depression and OCD, BrainsWay covers both under its clearances. That eliminates the need for separate treatment planning.

US Availability

MagVenture has stronger presence in academic medical centers, research hospitals, and European clinic networks. In the US, it’s more common at university-affiliated TMS centers and specialty psychiatric hospitals.

BrainsWay has broader commercial availability in private TMS clinics across the US. The device’s commercial footprint expanded significantly after the OCD clearance made it attractive for a wider patient population.

Use our provider directory to filter by device type and find clinics using either system in your area.

Insurance Considerations

Most major insurers cover both systems for major depressive disorder when criteria are met. The coverage landscape for OCD is where the devices diverge.

BrainsWay’s OCD clearance means insurers have a specific code to work with. MagVenture’s off-label OCD use requires more documentation and often triggers more scrutiny in the prior authorization process.

The Bottom Line

If OCD is part of your clinical picture, BrainsWay is the more practical choice. The dedicated clearance means fewer insurance fights and targeted protocols built specifically for that condition.

For depression alone, the decision comes down to what’s available at your clinic and your psychiatrist’s experience with each system. The clinical evidence doesn’t favor one over the other for standard MDD treatment.

Find a TMS clinic offering the system that’s right for your condition, or use our device comparison index to explore other options.


Key Takeaways

  • BrainsWay is the only TMS device with FDA clearance for OCD
  • MagVenture has stronger presence in academic and research settings
  • Depression outcomes are comparable between both platforms
  • BrainsWay's H-coil penetrates deeper brain structures
  • Insurance coverage for OCD is more straightforward with BrainsWay

Frequently Asked Questions

Is BrainsWay's deep TMS more effective than MagVenture's figure-8 for depression?

For depression specifically, no meaningful difference in response or remission rates has been established in head-to-head trials. Both are FDA-cleared and equally supported by evidence for treatment-resistant MDD.

Which device should I choose for OCD?

BrainsWay is the stronger choice for OCD because it has the only TMS-specific FDA clearance for the condition. That clearance streamlines insurance authorization and reflects dedicated clinical trial data for OCD patients.

Does my insurance cover BrainsWay or MagVenture TMS?

Most major insurers cover both for major depressive disorder when you meet treatment-resistant criteria. For OCD specifically, BrainsWay has a clearer path to coverage. Your clinic's billing department handles prior authorization and can verify coverage before treatment begins.

Can I request a specific TMS device at a clinic?

You can ask, but most clinics are equipped with one primary system and may not have both available. If the specific device matters to you, search providers by device type in our [clinic directory](/us/).

Ready to Find the Right TMS Provider?

Browse verified TMS clinics with detailed information about their devices, protocols, and insurance coverage.

Frequently Asked Questions

Which is better: MagVenture or BrainsWay?
The best option depends on your specific situation — diagnosis, treatment history, insurance coverage, and personal preferences. BrainsWay has unique OCD clearance via deep TMS. MagVenture has broader international reach and a strong research pedigree. Both produce comparable depression outcomes.
Can I try both treatments?
Yes, many patients try multiple approaches. Your psychiatrist can help you create a treatment plan that may include sequencing different options based on your response.
Does insurance cover both options?
Coverage varies by treatment and insurer. TMS is covered by most major insurance plans for depression. Other treatments may have different coverage requirements. Contact your insurer or a provider for a benefits check.
How do I choose the right treatment?
Start with a consultation with a psychiatrist who can evaluate your specific needs. Consider factors like effectiveness for your condition, side effect profile, time commitment, insurance coverage, and your personal preferences.

Related Resources

Find a TMS Clinic Near You

Browse verified providers with real patient reviews, insurance details, and treatment information.